KEGG   DRUG: Dolutegravir sodium and rilpivirine hydrochlorideHelp
Entry
D11282            Mixture   Drug                                   

Name
Dolutegravir sodium and rilpivirine hydrochloride;
Juluca (TN)
Product
Component
Dolutegravir sodium [DR:D10113], Rilpivirine hydrochloride [DR:D09958]
Remark
Therapeutic category: 6250
ATC code: J05AR21
Product: D11282<JP/US>
Efficacy
Antiviral
  Disease
HIV-1 infection [DS:H01563]
Comment
Dolutegravir is metabolized by UGT1A1 with some contribution from CYP3A; it is also an inhibitor of OCT2 and MATE1.
Rilpivirine is primarily metabolized by CYP3A.
Metabolism
Enzyme: CYP3A [HSA:1576 1577 1551], UGT1A1 [HSA:54658]
Interaction
Transporter inhibition: SLC22A2 [HSA:6582], SLC47A1 [hsa:55244]
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AR Antivirals for treatment of HIV infections, combinations
     J05AR21 Dolutegravir and rilpivirine
      D11282  Dolutegravir sodium and rilpivirine hydrochloride <JP/US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-HIV Agents, Other
   Dolutegravir/ Rilpivirine
    D11282  Dolutegravir sodium and rilpivirine hydrochloride
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D11282  Dolutegravir sodium and rilpivirine hydrochloride
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11282
BRITE hierarchy
Other DBs
PubChem: 384585260
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system